Mucopolysaccharidosis Type II Hunter Syndrome Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About Mucopolysaccharidosis Type II Hunter Syndrome
Hunter Syndrome, or MPS II, is a rare genetic disorder where the body lacks an essential enzyme, leading to progressive cell damage. Managing this condition requires ongoing, often expensive, treatments. TheDrugClub helps families and individuals make these vital medications more affordable, ensuring access to the care needed for a better quality of life.
Mucopolysaccharidosis Type II (MPS II), commonly known as Hunter Syndrome, is a rare, inherited genetic disorder primarily affecting boys. It's caused by a deficiency of the iduronate-2-sulfatase (IDS) enzyme. Without this crucial enzyme, complex sugar molecules called glycosaminoglycans (GAGs) cannot be properly broken down and accumulate in cells, tissues, and organs throughout the body. This progressive buildup leads to a wide range of symptoms and complications.
Symptoms of Hunter Syndrome can vary greatly in severity but often include distinctive facial features, skeletal abnormalities (such as joint stiffness and short stature), enlarged liver and spleen, respiratory problems, heart valve disease, and hearing loss. In more severe forms, neurological involvement can lead to developmental delays and cognitive decline.
While there is currently no cure for Hunter Syndrome, treatments are available to manage symptoms and improve quality of life. The primary treatment is Enzyme Replacement Therapy (ERT), using medications like Elaprase (idursulfase). ERT provides the missing IDS enzyme intravenously, helping to break down the accumulating GAGs. This can significantly improve many physical symptoms, such as organ size, joint mobility, and respiratory function. However, ERT typically does not cross the blood-brain barrier, meaning neurological symptoms may continue to progress in affected individuals. Other treatments focus on managing specific symptoms, including physical therapy, occupational therapy, surgical interventions for skeletal or organ issues, and supportive care for cardiac or respiratory complications.
The cost of these life-sustaining medications, especially ERT, can be extraordinarily high, placing a tremendous financial burden on families. This is where TheDrugClub steps in. For a low monthly membership fee – with a Drug Club membership
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.